Travere Therapeutics Inc Dossier - Source-backed chat

Travere Therapeutics Inc

TVTXNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.02

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $58.88Price as of 30 Sep 2026

Data confidenceNot applicable

Market Cap $5.6B

Enterprise Value $5.7B

Shares Outstanding 93.2M diluted

Moat Rating None

Next Earnings Date29 Oct 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Travere Therapeutics is transitioning from a clinical-stage biotech to a commercial-stage rare disease powerhouse. The investment thesis is anchored by the rapid commercial scaling of FILSPARI (sparsentan) in IgA Nephropathy (IgAN) and its recent landmark FDA approval in Focal Segmental Glomerulosclerosis (FSGS) in April 2026. With FILSPARI's peak sales potential estimated at over $3 billion in the U.S. alone, and the company achieving its first non-GAAP profitable quarter in Q1 2026, Travere offers a compelling combination of high-growth commercial assets and a de-risked pipeline, including the restarted Phase 3 HARMONY study for pegtibatinase.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets14 analysts · as of 18 Aug 2026

Low · most bearish analyst$49.00

Mean target$72.79

High · most bullish analyst$90.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$49.0015%

FILSPARI adoption slows due to competitive pressures from emerging therapies (e.g., from Novartis or Vera Therapeutics) or stricter payer reimbursement hurdles. The commercial launch in FSGS underperforms expectations. Clinical or regulatory setbacks in the pegtibatinase HARMONY study delay pipeline progression, forcing the company to consume cash faster and potentially seek dilutive financing.

Base CaseCentral scenario

$72.7960%

Matches the consensus mean

FILSPARI continues its strong commercial trajectory in IgAN, supported by robust PSF momentum, and establishes a solid foundation in FSGS. Pegtibatinase advances steadily through clinical development. The company maintains its path toward consistent non-GAAP profitability, supported by its solid cash position of $264.7 million (as of March 31, 2026) and milestone payments.

Bull CaseUpside scenario

$90.0025%

FILSPARI achieves rapid market penetration in both IgAN and the newly approved FSGS indication, exceeding peak sales expectations. The restarted Phase 3 HARMONY study for pegtibatinase delivers outstanding efficacy and safety data, paving the way for a third blockbuster rare disease product. Strong commercial execution drives sustained GAAP profitability ahead of schedule, leading to significant valuation multiple expansion.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

FILSPARI is the first and only non-immunosuppressive treatment proven to significantly slow kidney function decline in IgAN, and the first approved medicine for FSGS.
Robust commercial execution with Q1 2026 FILSPARI sales growing 88% year-over-year to $105.2 million, driving the company to its first non-GAAP profitable quarter.
De-risked pipeline with the restarted Phase 3 HARMONY study for pegtibatinase in classical HCU and the newly licensed civorebrutinib for rare kidney diseases.

Key Investment Risks

Intense competition in the IgAN space from established players and upcoming pipeline candidates from large pharmaceutical companies.
Commercial execution risks associated with launching FILSPARI in the newly approved FSGS indication.
High operational cash burn driven by R&D investments, such as the restarted Phase 3 HARMONY study.

Thesis Invalidation Triggers

A significant slowdown in FILSPARI new patient start forms (PSFs) or net product sales.
Failure or major delays in the Phase 3 HARMONY study of pegtibatinase.
Unexpected regulatory or safety issues arising from the real-world use of FILSPARI.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.